New treatments for colon cancer

Some errors occurred in this editorial by Maurice Slevin and Sarah Payne (17 July, pp 124-6). The misspelling of a drug persisted to publication—cetuximab was spelt wrongly throughout the article. The drug's manufacturer, Merck, has pointed out that the drug is licensed in many countries, not just Switzerland and the United States, as the article implied, and marketing authorisation was granted in the European Union at the end of June 2004.